Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier
Injectable nanoparticulate drug carriers (Np) able to cross the blood–brain barrier (BBB) have important potential applications for the treatment of diseases that affect the central nervous system (CNS). With the aim to create a system able to address Np to the CNS, we synthesized conjugates between...
Gespeichert in:
Veröffentlicht in: | Journal of controlled release 2005-11, Vol.108 (1), p.84-96 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 96 |
---|---|
container_issue | 1 |
container_start_page | 84 |
container_title | Journal of controlled release |
container_volume | 108 |
creator | Costantino, Luca Gandolfi, Francesca Tosi, Giovanni Rivasi, Francesco Vandelli, Maria Angela Forni, Flavio |
description | Injectable nanoparticulate drug carriers (Np) able to cross the blood–brain barrier (BBB) have important potential applications for the treatment of diseases that affect the central nervous system (CNS). With the aim to create a system able to address Np to the CNS, we synthesized conjugates between a biodegradable copolymer, poly(
d,
l-lactide-co-glycolide) (PLGA), and five short peptides, by means of an amidic linkage. These peptides, that are similar to synthetic opioid peptides, were synthesized in turn by means of Fmoc solid-phase peptide synthesis. The new five modified copolymers thus obtained turned out to be valuable starting material for the preparation of Np; these were made fluorescent, in order to allow their localization after their administration, by inclusion of a fluorescent probe. The Np thus prepared were characterized (morphology, size and
z-potential) and were shown to possess the peptidic moieties on their surface, as evidenced by ESCA spectroscopy. Then, their ability to cross the BBB was assessed by the in vivo
Rat Brain Perfusion Technique and, in one case, by means of a systemic administration (rat femoral vein injection). Fluorescent and confocal microscopy studies showed that while PLGA Np are unable to cross the BBB, for the first time these solid Np surface-modified with peptides were shown to be able to cross the BBB. |
doi_str_mv | 10.1016/j.jconrel.2005.07.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68710585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365905003305</els_id><sourcerecordid>68710585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-c7bd2500c65a3ac206e8119d3c66c147c2812d7f0671c9f063f613043d2765453</originalsourceid><addsrcrecordid>eNqF0MtO3DAUgGGrApUp9BGosoFdUt-drKoKQVsJqSxasbSc45PiUSae2hmkdtV34A15khomEktWlqzv-PITcspowyjTH9fNGuKUcGw4paqhpqFMvCEr1hpRy65TB2RVXFsLrboj8i7nNS1QSPOWHDHNlOScr8jtDW7n4LH2mMK9m8Nf9FUfosdfyXnXj1hNbopbl-YAI-bqeWuOFaSYczXfYdWPMfrHfw99cmGqepdSwHRCDgc3Zny_rMfk59Xlj4uv9fX3L98uPl_XILmcazC954pS0MoJB5xqbBnrvACtgUkDvGXcm4Fqw6Arixg0E1QKz41WUoljcr4_d5vi7x3m2W5CBhxHN2HcZatbw6hqX4esk0qZThao9vD5hwkHu01h49Ify6h9Sm_Xdklvn9JbamxJX-Y-LBfs-g36l6mldQFnC3AZ3DgkN0HIL85wabTWxX3aOyzd7ktLmyHgBOhDQpitj-GVp_wH6ymlHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19455794</pqid></control><display><type>article</type><title>Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Costantino, Luca ; Gandolfi, Francesca ; Tosi, Giovanni ; Rivasi, Francesco ; Vandelli, Maria Angela ; Forni, Flavio</creator><creatorcontrib>Costantino, Luca ; Gandolfi, Francesca ; Tosi, Giovanni ; Rivasi, Francesco ; Vandelli, Maria Angela ; Forni, Flavio</creatorcontrib><description>Injectable nanoparticulate drug carriers (Np) able to cross the blood–brain barrier (BBB) have important potential applications for the treatment of diseases that affect the central nervous system (CNS). With the aim to create a system able to address Np to the CNS, we synthesized conjugates between a biodegradable copolymer, poly(
d,
l-lactide-co-glycolide) (PLGA), and five short peptides, by means of an amidic linkage. These peptides, that are similar to synthetic opioid peptides, were synthesized in turn by means of Fmoc solid-phase peptide synthesis. The new five modified copolymers thus obtained turned out to be valuable starting material for the preparation of Np; these were made fluorescent, in order to allow their localization after their administration, by inclusion of a fluorescent probe. The Np thus prepared were characterized (morphology, size and
z-potential) and were shown to possess the peptidic moieties on their surface, as evidenced by ESCA spectroscopy. Then, their ability to cross the BBB was assessed by the in vivo
Rat Brain Perfusion Technique and, in one case, by means of a systemic administration (rat femoral vein injection). Fluorescent and confocal microscopy studies showed that while PLGA Np are unable to cross the BBB, for the first time these solid Np surface-modified with peptides were shown to be able to cross the BBB.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2005.07.013</identifier><identifier>PMID: 16154222</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Biocompatible Materials - administration & dosage ; Biocompatible Materials - chemistry ; Biocompatible Materials - pharmacokinetics ; Biological and medical sciences ; Blood-Brain Barrier - metabolism ; Blood–brain barrier ; Drug Carriers - administration & dosage ; Drug Carriers - chemistry ; Drug Carriers - pharmacokinetics ; Drug Compounding ; General pharmacology ; Injections, Intravenous ; Medical sciences ; Microscopy, Electron ; Microscopy, Fluorescence ; Nanoparticles ; Nanostructures ; Oligopeptides - administration & dosage ; Oligopeptides - chemistry ; Oligopeptides - pharmacokinetics ; Peptides ; Perfusion ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; PLGA ; Polyglactin 910 - administration & dosage ; Polyglactin 910 - chemistry ; Polyglactin 910 - pharmacokinetics ; Rats ; Surface Properties ; Targeting</subject><ispartof>Journal of controlled release, 2005-11, Vol.108 (1), p.84-96</ispartof><rights>2005 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-c7bd2500c65a3ac206e8119d3c66c147c2812d7f0671c9f063f613043d2765453</citedby><cites>FETCH-LOGICAL-c424t-c7bd2500c65a3ac206e8119d3c66c147c2812d7f0671c9f063f613043d2765453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2005.07.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17247666$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16154222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costantino, Luca</creatorcontrib><creatorcontrib>Gandolfi, Francesca</creatorcontrib><creatorcontrib>Tosi, Giovanni</creatorcontrib><creatorcontrib>Rivasi, Francesco</creatorcontrib><creatorcontrib>Vandelli, Maria Angela</creatorcontrib><creatorcontrib>Forni, Flavio</creatorcontrib><title>Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Injectable nanoparticulate drug carriers (Np) able to cross the blood–brain barrier (BBB) have important potential applications for the treatment of diseases that affect the central nervous system (CNS). With the aim to create a system able to address Np to the CNS, we synthesized conjugates between a biodegradable copolymer, poly(
d,
l-lactide-co-glycolide) (PLGA), and five short peptides, by means of an amidic linkage. These peptides, that are similar to synthetic opioid peptides, were synthesized in turn by means of Fmoc solid-phase peptide synthesis. The new five modified copolymers thus obtained turned out to be valuable starting material for the preparation of Np; these were made fluorescent, in order to allow their localization after their administration, by inclusion of a fluorescent probe. The Np thus prepared were characterized (morphology, size and
z-potential) and were shown to possess the peptidic moieties on their surface, as evidenced by ESCA spectroscopy. Then, their ability to cross the BBB was assessed by the in vivo
Rat Brain Perfusion Technique and, in one case, by means of a systemic administration (rat femoral vein injection). Fluorescent and confocal microscopy studies showed that while PLGA Np are unable to cross the BBB, for the first time these solid Np surface-modified with peptides were shown to be able to cross the BBB.</description><subject>Animals</subject><subject>Biocompatible Materials - administration & dosage</subject><subject>Biocompatible Materials - chemistry</subject><subject>Biocompatible Materials - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Blood–brain barrier</subject><subject>Drug Carriers - administration & dosage</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Carriers - pharmacokinetics</subject><subject>Drug Compounding</subject><subject>General pharmacology</subject><subject>Injections, Intravenous</subject><subject>Medical sciences</subject><subject>Microscopy, Electron</subject><subject>Microscopy, Fluorescence</subject><subject>Nanoparticles</subject><subject>Nanostructures</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - chemistry</subject><subject>Oligopeptides - pharmacokinetics</subject><subject>Peptides</subject><subject>Perfusion</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>PLGA</subject><subject>Polyglactin 910 - administration & dosage</subject><subject>Polyglactin 910 - chemistry</subject><subject>Polyglactin 910 - pharmacokinetics</subject><subject>Rats</subject><subject>Surface Properties</subject><subject>Targeting</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0MtO3DAUgGGrApUp9BGosoFdUt-drKoKQVsJqSxasbSc45PiUSae2hmkdtV34A15khomEktWlqzv-PITcspowyjTH9fNGuKUcGw4paqhpqFMvCEr1hpRy65TB2RVXFsLrboj8i7nNS1QSPOWHDHNlOScr8jtDW7n4LH2mMK9m8Nf9FUfosdfyXnXj1hNbopbl-YAI-bqeWuOFaSYczXfYdWPMfrHfw99cmGqepdSwHRCDgc3Zny_rMfk59Xlj4uv9fX3L98uPl_XILmcazC954pS0MoJB5xqbBnrvACtgUkDvGXcm4Fqw6Arixg0E1QKz41WUoljcr4_d5vi7x3m2W5CBhxHN2HcZatbw6hqX4esk0qZThao9vD5hwkHu01h49Ify6h9Sm_Xdklvn9JbamxJX-Y-LBfs-g36l6mldQFnC3AZ3DgkN0HIL85wabTWxX3aOyzd7ktLmyHgBOhDQpitj-GVp_wH6ymlHg</recordid><startdate>20051102</startdate><enddate>20051102</enddate><creator>Costantino, Luca</creator><creator>Gandolfi, Francesca</creator><creator>Tosi, Giovanni</creator><creator>Rivasi, Francesco</creator><creator>Vandelli, Maria Angela</creator><creator>Forni, Flavio</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20051102</creationdate><title>Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier</title><author>Costantino, Luca ; Gandolfi, Francesca ; Tosi, Giovanni ; Rivasi, Francesco ; Vandelli, Maria Angela ; Forni, Flavio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-c7bd2500c65a3ac206e8119d3c66c147c2812d7f0671c9f063f613043d2765453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Biocompatible Materials - administration & dosage</topic><topic>Biocompatible Materials - chemistry</topic><topic>Biocompatible Materials - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Blood–brain barrier</topic><topic>Drug Carriers - administration & dosage</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Carriers - pharmacokinetics</topic><topic>Drug Compounding</topic><topic>General pharmacology</topic><topic>Injections, Intravenous</topic><topic>Medical sciences</topic><topic>Microscopy, Electron</topic><topic>Microscopy, Fluorescence</topic><topic>Nanoparticles</topic><topic>Nanostructures</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - chemistry</topic><topic>Oligopeptides - pharmacokinetics</topic><topic>Peptides</topic><topic>Perfusion</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>PLGA</topic><topic>Polyglactin 910 - administration & dosage</topic><topic>Polyglactin 910 - chemistry</topic><topic>Polyglactin 910 - pharmacokinetics</topic><topic>Rats</topic><topic>Surface Properties</topic><topic>Targeting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costantino, Luca</creatorcontrib><creatorcontrib>Gandolfi, Francesca</creatorcontrib><creatorcontrib>Tosi, Giovanni</creatorcontrib><creatorcontrib>Rivasi, Francesco</creatorcontrib><creatorcontrib>Vandelli, Maria Angela</creatorcontrib><creatorcontrib>Forni, Flavio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costantino, Luca</au><au>Gandolfi, Francesca</au><au>Tosi, Giovanni</au><au>Rivasi, Francesco</au><au>Vandelli, Maria Angela</au><au>Forni, Flavio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2005-11-02</date><risdate>2005</risdate><volume>108</volume><issue>1</issue><spage>84</spage><epage>96</epage><pages>84-96</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>Injectable nanoparticulate drug carriers (Np) able to cross the blood–brain barrier (BBB) have important potential applications for the treatment of diseases that affect the central nervous system (CNS). With the aim to create a system able to address Np to the CNS, we synthesized conjugates between a biodegradable copolymer, poly(
d,
l-lactide-co-glycolide) (PLGA), and five short peptides, by means of an amidic linkage. These peptides, that are similar to synthetic opioid peptides, were synthesized in turn by means of Fmoc solid-phase peptide synthesis. The new five modified copolymers thus obtained turned out to be valuable starting material for the preparation of Np; these were made fluorescent, in order to allow their localization after their administration, by inclusion of a fluorescent probe. The Np thus prepared were characterized (morphology, size and
z-potential) and were shown to possess the peptidic moieties on their surface, as evidenced by ESCA spectroscopy. Then, their ability to cross the BBB was assessed by the in vivo
Rat Brain Perfusion Technique and, in one case, by means of a systemic administration (rat femoral vein injection). Fluorescent and confocal microscopy studies showed that while PLGA Np are unable to cross the BBB, for the first time these solid Np surface-modified with peptides were shown to be able to cross the BBB.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16154222</pmid><doi>10.1016/j.jconrel.2005.07.013</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2005-11, Vol.108 (1), p.84-96 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_68710585 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Biocompatible Materials - administration & dosage Biocompatible Materials - chemistry Biocompatible Materials - pharmacokinetics Biological and medical sciences Blood-Brain Barrier - metabolism Blood–brain barrier Drug Carriers - administration & dosage Drug Carriers - chemistry Drug Carriers - pharmacokinetics Drug Compounding General pharmacology Injections, Intravenous Medical sciences Microscopy, Electron Microscopy, Fluorescence Nanoparticles Nanostructures Oligopeptides - administration & dosage Oligopeptides - chemistry Oligopeptides - pharmacokinetics Peptides Perfusion Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments PLGA Polyglactin 910 - administration & dosage Polyglactin 910 - chemistry Polyglactin 910 - pharmacokinetics Rats Surface Properties Targeting |
title | Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T01%3A05%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide-derivatized%20biodegradable%20nanoparticles%20able%20to%20cross%20the%20blood%E2%80%93brain%20barrier&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Costantino,%20Luca&rft.date=2005-11-02&rft.volume=108&rft.issue=1&rft.spage=84&rft.epage=96&rft.pages=84-96&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/j.jconrel.2005.07.013&rft_dat=%3Cproquest_cross%3E68710585%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19455794&rft_id=info:pmid/16154222&rft_els_id=S0168365905003305&rfr_iscdi=true |